Clinical trials: Apixaban
Venous Thromboembolic Disease, Kidney Failure, Chronic
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
Patients with end stage renal disease (ESRD) are at significantly increased risk of thrombosis and bleeding relative to those with normal renal function which makes anticoagulation particularly challenging.
- Trial name
- NCT04818151
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 14,914 people
- Sponsor
- Johns Hopkins University
Anticoagulation
Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France
The present study will be conducted to assess the following research questions in real-life conditions in France: What are the patient and disease characteristics, comorbidities and treatment history in NVAF patients initiating a…
- Trial name
- NCT02714855
- Testing
- Apixaban
- Where
- France
- Volunteers
- 2,081 people
- Sponsor
- Bristol-Myers Squibb
Bleeding
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
This is a randomized, double-blind, study in healthy volunteers dosed to steady state with fXa inhibitors, designed to (1) demonstrate PK/PD comparability between andexanet manufactured by the Generation 1 and Generation 2…
- Trial name
- NCT03083704
- Testing
- Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Atrial Fibrillation
Atrial Fibrillation Patient Preference Study
The main research question of this patient survey is to assess AF patients' preferences associated with different attributes which describe the different available anticoagulation treatment options (VKA or NOACs and, in case of…
- Trial name
- PRiSMA-AF (NCT02611635)
- Testing
- VKA: Warfarin (Waran), NOAC: Rivaroxaban (Xarelto, BAY59-7939), NOAC: Dabigatran etexilate
- Where
- Sweden
- Volunteers
- 382 people
- Sponsor
- Bayer
Thrombosis, Deep Vein, Pulmonary Embolism
A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment
Number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with apixaban, according to therapeutic indications approved in Mexico.
- Trial name
- NCT03812835
- Sponsor
- Pfizer
COVID-19, SARS-CoV-2
FREEDOM COVID-19 Anticoagulation Strategy
Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era.
- Trial name
- FREEDOM COVID (NCT04512079)
- Testing
- Enoxaparin, Apixaban
- Where
- 21 sites in United States, Brazil and 3 more
- Volunteers
- 3,460 people
- Sponsor
- Valentin Fuster
Patent Foramen Ovale, Cardiac Implantable Electronic Device
Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
Patients with a patent foramen ovale in the setting of endocardially placed cardiac implantable electronic devices such as pacemakers, defibrillators, or resynchronization therapies are likely at higher risk for paradoxical…
- Trial name
- PARADOX (NCT02378623)
- Testing
- Apixaban
- Where
- United States
- Sponsor
- Mayo Clinic
Intracerebral Hemorrhage, Atrial Fibrillation
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).
- Trial name
- ASPIRE (NCT03907046)
- Testing
- Apixaban, Aspirin
- Where
- 187 sites in United States
- Volunteers
- 700 people
- Sponsor
- Yale University
Acute Ischemic Stroke
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy…
- Trial name
- NCT04809818
- Testing
- LT3001 drug product, Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Left Ventricular Thrombus
Apixaban Versus Warfarin for Left Ventricular Thrombus
Left ventricular thrombus is a blood clot that forms in the left ventricle and is associated with risk of systemic embolism and ischemic stroke.
- Trial name
- APEX (NCT07709780)
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 218 people
- Sponsor
- University of Arizona
Atrial Fibrillation, Frailty
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
The objective of this study is to establish a near-real-time prospective monitoring program in Medicare, Optum and MarketScan Research data to evaluate the benefit of new cardiovascular disease (CVD) drugs for older adults with…
- Conditions
- Atrial Fibrillation, Frailty, Anticoagulant-induced Bleeding, Stroke
- Trial name
- NCT04878497
- Testing
- Warfarin, Dabigatran, Rivaroxaban
- Where
- United States
- Volunteers
- 1,000,000 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism, Anticoagulants
Apixaban for Extended Anticoagulation (APIDULCIS)
The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism) (VTE).
- Trial name
- APIDULCIS (NCT03678506)
- Testing
- Apixaban
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Arianna Anticoagulazione Foundation
Knee Arthroplasty, Total
FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
This study was to compare the study drug BAY1213790 to existing therapies, i.e. enoxaparin or apixaban, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
- Trial name
- FOXTROT (NCT03276143)
- Testing
- Enoxaparin, Apixaban, BAY1213790
- Where
- 54 sites in Bulgaria, Canada and 11 more
- Volunteers
- 813 people
- Sponsor
- Bayer
Deep Venous Thrombosis, Pulmonary Embolism
The DARE Warfarin CER Study
Approximately half a million Americans annually experience venous thromboembolic disease, including deep venous thrombosis (DVT) and pulmonary embolism (PE).
- Trial name
- NCT03271450
- Testing
- Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days)
- Where
- United States
- Volunteers
- 416,000 people
- Sponsor
- Brigham and Women's Hospital
Cirrhosis, Splenectomy; Status
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
The purpose of this study is to determine whether Apixaban, Warfarin and Aspirin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy
- Conditions
- Cirrhosis, Splenectomy; Status, Venous Thrombosis, Hypertension, Portal
- Trial name
- NCT04645550
- Testing
- Apixaban, Warfarin, Aspirin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Northern Jiangsu People's Hospital
Liver Cirrhosis
DOAC in Patients with Child a or B Liver Cirrhosis
The goal of this clinical trial is to investigate pharmacokinetics and pharmacodynamics of direct oral anticoagulant drugs (DOAC), specifically apixaban and edoxaban, in patients with Child A or B liver cirrhosis (LC).
- Trial name
- CIRROAC (NCT05869591)
- Testing
- Apixaban 5 MG [Eliquis], Edoxaban 60 MG [Lixiana]
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Atrial Fibrillation
Pharmacokinetics of Apixaban in Peritoneal Dialysis
Atrial fibrillation (AF) is fairly prevalent in patients with end stage renal disease (ESRD) with the prevalence estimated to be 3.8 - 27%.
- Trial name
- NCT05532878
- Testing
- Apixaban
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- Chinese University of Hong Kong
Complication
Prevention of Complications (SARS-CoV-2): Clinical Study
Viral diseases have always posed a threat to public health. Recently, the SARS-Cov2 virus spread in an epidemic that began in China and soon spread globally, making its study extremely relevant, in order to seek mechanisms to…
- Trial name
- NCT04788355
- Testing
- Control group (standard hospital treatment), Group Hydroxychloroquine, Group Hydroxychloroquine and apixaban
- Where
- Brazil
- Volunteers
- 176 people
- Sponsor
- Universidade do Vale do Sapucai
Venous Thromboembolism
Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism.
- Trial name
- COVET (NCT03196349)
- Testing
- Warfarin, Apixaban 2.5 MG, Rivaroxaban 10 MG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Duke University
Anticoagulants and Bleeding Disorders, Atrial Fibrillation
Atrial Fibrillation Research Database
All patients with atrial fibrillation who are treated with vitamin-k antagonists (warfarin, phenprocoumon) or non vitamin K oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in real world settings will be recorded…
- Trial name
- NCT03760874
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- University of Campania Luigi Vanvitelli